Showing results (1761-1770 of 1,874) with videos related to

Sort By:
Pageof 188
Clinical Lung Cancer|May 8, 2019
Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life CohortElizabeth Dudnik, Jair Bar, Nir Peled, et al.
Cancer Research|October 31, 2012
A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced diseaseDiego J Laderach, Lucas D Gentilini, Laura Giribaldi, et al.
Annals of Surgical Oncology|April 6, 2021
The Clinical Utility of DCISionRT® on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving SurgeryChirag Shah, Troy Bremer, Charles Cox, et al.
Hematological Oncology|August 4, 2021
Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysisChristopher R D'Angelo, Walter Hanel, Yi Chen, et al.
Scientific Reports|March 16, 2017
Down regulation of ADAM33 as a Predictive Biomarker of Aggressive Breast CancerGraciele C M Manica, Caroline F Ribeiro, Marco A S de Oliveira, et al.
Viruses|January 19, 2018
Biomarkers of Progression after HIV Acute/Early Infection: Nothing Compares to CD4⁺ T-cell Count?Gabriela Turk, Yanina Ghiglione, Macarena Hormanstorfer, et al.
The Journal of Rheumatology|February 4, 2003
Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosisSuzanne L Bowyer, Philip A Roettcher, Gloria C Higgins, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 2, 2025
Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cellsJudith Vinaixa, Neus Martínez-Bosch, Joan Gibert, et al.
Nature Medicine|March 5, 2013
Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletionYared Hailemichael, Zhimin Dai, Nina Jaffarzad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2012
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivoFiona Simpkins, Pedro Hevia-Paez, Jun Sun, et al.
Pageof 188